AAPL325.69+0.56 (+0.17%) ▲|ABBV260.34+0.35 (+0.13%) ▲|ABT110.89+1.96 (+1.80%) ▲|ACN187.69-0.40 (-0.21%) ▼|ADBE280.82-5.27 (-1.84%) ▼|AMAT438.52-3.33 (-0.75%) ▼|AMD456.62-2.99 (-0.65%) ▼|AMGN441.36+3.24 (+0.74%) ▲|AMT172.50-3.53 (-2.00%) ▼|AMZN255.12+0.20 (+0.08%) ▲|AVGO368.94-0.75 (-0.20%) ▼|AXP329.70+5.51 (+1.70%) ▲|BA208.84+3.18 (+1.55%) ▲|BAC62.64+0.65 (+1.05%) ▲|BKNG199.42+3.73 (+1.91%) ▲|BLK1,111.54-16.56 (-1.47%) ▼|BMY67.71+0.79 (+1.18%) ▲|BNY162.20+1.69 (+1.05%) ▲|BRK-B505.20+2.87 (+0.57%) ▲|C134.30+1.76 (+1.33%) ▲|CAT790.36+11.20 (+1.44%) ▲|CL90.23+0.60 (+0.67%) ▲|CMCSA26.88+0.58 (+2.19%) ▲|COF216.92+5.58 (+2.64%) ▲|COP137.24+1.05 (+0.77%) ▲|COST921.73-18.23 (-1.94%) ▼|CRM258.33+0.22 (+0.09%) ▲|CSCO109.47-0.27 (-0.25%) ▼|CVS97.19-0.41 (-0.42%) ▼|CVX212.49+1.44 (+0.68%) ▲|DE691.98+15.90 (+2.35%) ▲|DHR209.65+2.72 (+1.31%) ▲|DIS108.46+2.24 (+2.11%) ▲|DUK120.57+0.18 (+0.15%) ▲|EMR149.10+1.47 (+1.00%) ▲|FDX317.89-6.99 (-2.15%) ▼|GD365.98-3.43 (-0.93%) ▼|GE330.31-0.78 (-0.24%) ▼|GEV921.89+23.36 (+2.60%) ▲|GILD149.58-0.35 (-0.23%) ▼|GM84.80-0.84 (-0.98%) ▼|GOOG334.31+2.28 (+0.69%) ▲|GOOGL337.76+2.74 (+0.82%) ▲|GS1,005.10+2.54 (+0.25%) ▲|HD317.95-1.82 (-0.57%) ▼|HON205.35-4.63 (-2.21%) ▼|IBM231.78+0.38 (+0.16%) ▲|INTC89.77+0.80 (+0.90%) ▲|INTU343.00-1.94 (-0.56%) ▼|ISRG370.69+1.44 (+0.39%) ▲|JNJ275.44+4.25 (+1.57%) ▲|JPM355.86+0.91 (+0.26%) ▲|KO88.57+0.57 (+0.64%) ▲|LIN488.47+1.71 (+0.35%) ▲|LLY1,164.70+4.70 (+0.41%) ▲|LMT533.83-10.68 (-1.96%) ▼|LOW199.95-0.10 (-0.05%) ▼|LRCX287.31-2.90 (-1.00%) ▼|MA588.70+7.60 (+1.31%) ▲|MCD260.27-0.85 (-0.32%) ▼|MDLZ62.53+0.92 (+1.49%) ▲|MDT92.84+0.80 (+0.87%) ▲|META595.21+16.67 (+2.88%) ▲|MMM168.31-1.93 (-1.13%) ▼|MO69.67+0.10 (+0.14%) ▲|MRK151.69+1.83 (+1.22%) ▲|MS212.29+1.25 (+0.59%) ▲|MSFT496.75-4.27 (-0.85%) ▼|MU952.16+18.72 (+2.00%) ▲|NEE82.93-0.01 (-0.01%) ▼|NFLX82.39+1.58 (+1.95%) ▲|NKE38.25+0.13 (+0.33%) ▲|NOW137.17-5.73 (-4.01%) ▼|NVDA224.69+7.25 (+3.33%) ▲|ORCL146.16+4.84 (+3.42%) ▲|PEP140.42+0.63 (+0.45%) ▲|PFE29.04+0.49 (+1.72%) ▲|PG147.61+1.40 (+0.96%) ▲|PLTR169.24-10.68 (-5.94%) ▼|PM187.20+0.05 (+0.02%) ▲|QCOM169.75+3.14 (+1.88%) ▲|RTX201.54-3.63 (-1.77%) ▼|SBUX107.13+0.98 (+0.92%) ▲|SCHW109.00+0.72 (+0.66%) ▲|SO88.25+0.16 (+0.18%) ▲|SPG209.49-2.38 (-1.12%) ▼|T26.04+0.04 (+0.14%) ▲|TMO608.84+8.34 (+1.39%) ▲|TMUS186.77+4.61 (+2.53%) ▲|TSLA352.94-3.15 (-0.88%) ▼|TXN254.76+1.42 (+0.56%) ▲|UBER76.64+1.40 (+1.86%) ▲|UNH399.82+3.52 (+0.89%) ▲|UNP290.59-0.03 (-0.01%) ▼|UPS103.15+0.49 (+0.48%) ▲|USB62.83+1.62 (+2.65%) ▲|V379.85+7.18 (+1.93%) ▲|VZ50.35+0.05 (+0.11%) ▲|WFC89.66+2.62 (+3.01%) ▲|WMT105.92-0.01 (0.00%) ▼|XOM164.92+0.37 (+0.22%) ▲|AAPL325.69+0.56 (+0.17%) ▲|ABBV260.34+0.35 (+0.13%) ▲|ABT110.89+1.96 (+1.80%) ▲|ACN187.69-0.40 (-0.21%) ▼|ADBE280.82-5.27 (-1.84%) ▼|AMAT438.52-3.33 (-0.75%) ▼|AMD456.62-2.99 (-0.65%) ▼|AMGN441.36+3.24 (+0.74%) ▲|AMT172.50-3.53 (-2.00%) ▼|AMZN255.12+0.20 (+0.08%) ▲|AVGO368.94-0.75 (-0.20%) ▼|AXP329.70+5.51 (+1.70%) ▲|BA208.84+3.18 (+1.55%) ▲|BAC62.64+0.65 (+1.05%) ▲|BKNG199.42+3.73 (+1.91%) ▲|BLK1,111.54-16.56 (-1.47%) ▼|BMY67.71+0.79 (+1.18%) ▲|BNY162.20+1.69 (+1.05%) ▲|BRK-B505.20+2.87 (+0.57%) ▲|C134.30+1.76 (+1.33%) ▲|CAT790.36+11.20 (+1.44%) ▲|CL90.23+0.60 (+0.67%) ▲|CMCSA26.88+0.58 (+2.19%) ▲|COF216.92+5.58 (+2.64%) ▲|COP137.24+1.05 (+0.77%) ▲|COST921.73-18.23 (-1.94%) ▼|CRM258.33+0.22 (+0.09%) ▲|CSCO109.47-0.27 (-0.25%) ▼|CVS97.19-0.41 (-0.42%) ▼|CVX212.49+1.44 (+0.68%) ▲|DE691.98+15.90 (+2.35%) ▲|DHR209.65+2.72 (+1.31%) ▲|DIS108.46+2.24 (+2.11%) ▲|DUK120.57+0.18 (+0.15%) ▲|EMR149.10+1.47 (+1.00%) ▲|FDX317.89-6.99 (-2.15%) ▼|GD365.98-3.43 (-0.93%) ▼|GE330.31-0.78 (-0.24%) ▼|GEV921.89+23.36 (+2.60%) ▲|GILD149.58-0.35 (-0.23%) ▼|GM84.80-0.84 (-0.98%) ▼|GOOG334.31+2.28 (+0.69%) ▲|GOOGL337.76+2.74 (+0.82%) ▲|GS1,005.10+2.54 (+0.25%) ▲|HD317.95-1.82 (-0.57%) ▼|HON205.35-4.63 (-2.21%) ▼|IBM231.78+0.38 (+0.16%) ▲|INTC89.77+0.80 (+0.90%) ▲|INTU343.00-1.94 (-0.56%) ▼|ISRG370.69+1.44 (+0.39%) ▲|JNJ275.44+4.25 (+1.57%) ▲|JPM355.86+0.91 (+0.26%) ▲|KO88.57+0.57 (+0.64%) ▲|LIN488.47+1.71 (+0.35%) ▲|LLY1,164.70+4.70 (+0.41%) ▲|LMT533.83-10.68 (-1.96%) ▼|LOW199.95-0.10 (-0.05%) ▼|LRCX287.31-2.90 (-1.00%) ▼|MA588.70+7.60 (+1.31%) ▲|MCD260.27-0.85 (-0.32%) ▼|MDLZ62.53+0.92 (+1.49%) ▲|MDT92.84+0.80 (+0.87%) ▲|META595.21+16.67 (+2.88%) ▲|MMM168.31-1.93 (-1.13%) ▼|MO69.67+0.10 (+0.14%) ▲|MRK151.69+1.83 (+1.22%) ▲|MS212.29+1.25 (+0.59%) ▲|MSFT496.75-4.27 (-0.85%) ▼|MU952.16+18.72 (+2.00%) ▲|NEE82.93-0.01 (-0.01%) ▼|NFLX82.39+1.58 (+1.95%) ▲|NKE38.25+0.13 (+0.33%) ▲|NOW137.17-5.73 (-4.01%) ▼|NVDA224.69+7.25 (+3.33%) ▲|ORCL146.16+4.84 (+3.42%) ▲|PEP140.42+0.63 (+0.45%) ▲|PFE29.04+0.49 (+1.72%) ▲|PG147.61+1.40 (+0.96%) ▲|PLTR169.24-10.68 (-5.94%) ▼|PM187.20+0.05 (+0.02%) ▲|QCOM169.75+3.14 (+1.88%) ▲|RTX201.54-3.63 (-1.77%) ▼|SBUX107.13+0.98 (+0.92%) ▲|SCHW109.00+0.72 (+0.66%) ▲|SO88.25+0.16 (+0.18%) ▲|SPG209.49-2.38 (-1.12%) ▼|T26.04+0.04 (+0.14%) ▲|TMO608.84+8.34 (+1.39%) ▲|TMUS186.77+4.61 (+2.53%) ▲|TSLA352.94-3.15 (-0.88%) ▼|TXN254.76+1.42 (+0.56%) ▲|UBER76.64+1.40 (+1.86%) ▲|UNH399.82+3.52 (+0.89%) ▲|UNP290.59-0.03 (-0.01%) ▼|UPS103.15+0.49 (+0.48%) ▲|USB62.83+1.62 (+2.65%) ▲|V379.85+7.18 (+1.93%) ▲|VZ50.35+0.05 (+0.11%) ▲|WFC89.66+2.62 (+3.01%) ▲|WMT105.92-0.01 (0.00%) ▼|XOM164.92+0.37 (+0.22%) ▲|
22.6 C
New York
Wednesday, September 2, 2026

Tag: products

newssourceFORcompanyinformationcontent1releasesmarket

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

BRIDGEWATER, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced first clinical proof-of-concept data for LB2501, its investigational in vivo CD19/CD20 dual-targeting CAR-T cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). The results are being presented today in a late-breaking session at the European Hematology Association (EHA) 2026 Congress (Abstract #LB5006).

Rally House Ready with New York Knicks Championship Gear Following NBA Finals Victory

Rally House locations across New York will have NBA Champions Gear starting first thing Sunday 6/14. Shop online now.

ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Zoetis Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ZTS

NEW YORK, June 13, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Zoetis Inc. (NYSE: ZTS) between January 14, 2025 and May 6, 2026, inclusive (the “Class Period”), of the important July 27, 2026 lead plaintiff deadline.

BABCOCK & WILCOX DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Babcock & Wilcox Enterprises, Inc. Investors to Secure Counsel Before Important June 15 Deadline in...

NEW YORK, June 13, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Babcock & Wilcox Enterprises, Inc. (“B&W”) (NYSE: BW) between November 5, 2025 and March 11, 2026, inclusive (the “Class Period”), of the important June 15, 2026 lead plaintiff deadline.

Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism

COPENHAGEN, Denmark, June 13, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced Week 182 data from its completed Phase 3 PaTHway Trial showing that long-term treatment with TransCon PTH (palopegteriparatide) demonstrated sustained efficacy and safety in adults with hypoparathyroidism. Over the three-and-a-half-year duration of the trial, TransCon PTH replicated the systemic actions of endogenous PTH, with a balanced, beneficial impact on the main target organ systems – CNS, kidney, small intestine, and bone – as demonstrated by improved quality of life and normalized and stable urine calcium, serum calcium, serum phosphate, and bone mineral density. These benefits were sustained while enabling independence from conventional therapy with active vitamin D and calcium.

Glacier Breeze Portable AC: Features, Performance Claims & Consumer Feedback Evaluated in 2026

Madrid, Spain, June 13, 2026 (GLOBE NEWSWIRE) -- A 2026 company-aligned overview of how the Glacier Breeze Portable AC is presented across official product materials, including its Twin Frost Jet design, evaporative cooling technology, cooling cartridge system, and key considerations for consumers before purchasing.

Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Media Release

COPENHAGEN, Denmark; June 13, 2026

HeroMD 4-MAX Claims Evaluated: Why Men Searching “Most Effective 4-in-1 Erectile Dysfunction Formula” Are Comparing SURGE, PRIME and The HERO System Explained

HeroMD 4-MAX scam or legit? Compounded 4-in-1 sublingual ED formula with 10-min onset and 36-hr window reviewed.

MGI Tech Showcases Expanding Genomics Ecosystem at ESHG 2026 with New IVD Partnering Program and OEM Collaborations

GOTHENBURG, Sweden, June 13, 2026 /PRNewswire/ -- MGI Tech Co., Ltd. (MGI), a company committed to developing core tools and technologies that drive innovation...

PureHealth Research Utilizes Bioavailable Cranberry and Astragalus in Premium Natural Supplements for Kidney Health

MANASSAS, Va., June 13, 2026 /PRNewswire/ -- PureHealth Research today addressed the growing demand for proactive kidney wellness with its collection of science-backed renal...

VEVOR Launches “Beat the Heat at Home” Summer Comfort Lineup for Outdoor Living

HOUSTON, June 13, 2026 /PRNewswire/ -- As summer temperatures climb, staying cool at home shouldn't require a sky-high electric bill, a cooler full of...

Don’t Pay Full Price for Power: WattCycle’s Prime Day Event Drops Up to 70% Off LiFePO4 Batteries Starting June 15

WattCycle’s June 15-30 sale offers up to 70% off LiFePO4 batteries. Enjoy new arrivals, double points, giveaways & 8% off code: WattCyclePrimeDay.

 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026

 -- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean mass, and improvements in hyperphagia and anxiety measures --   

-- Positive results reinforce rationale for Phase 3 development of MC4R agonism in PWS --

SpaceX perpetual futures become Binance’s No. 2 traded product; Binance captures over 60% market share across CEX and DEX venues

Binance exceeded $5.6 billion in SPCXUSDT trading volume over last 24 hours, with over $9 billion in accumulated trading volume across SpaceX's Pre-IPO and...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsProducts

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers